To Assess the Role of Fecal Microbiota Transplant in Acute Liver Failure

Status Withdrawn

Clinical Trial Summary

All patients of Acute liver failure not meeting the KCH (King's College Hospital) criteria/or meeting KCH criteria not having option of liver transplant will be recruited for the trial. The first group will receive Standard medical care with Fecal Microbiota transplant on Day 1 for 3 consecutive days. FMT (Fecal Microbiota Transplant) will be delivered rectally which will be placed bedside. Suitable donor will be screened and the stool samples will be used as per criteria. Stool samples will be taken at the time at Day 0, 1(Post FMT), Day 4, 6, 14,21. Sepsis screen will be sent. Inflammatory markers will be sent on Day 0,1, 4,6, 14,21. The second group will receive standard medical therapy/and an placebo. Stool samples will be sent on Day 0,1, 4, 6 , 14,21. Inflammatory markers will be sent on the time on day 0,1 4,6 , 14,21.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03363022
Study type	Interventional
Source	Institute of Liver and Biliary Sciences, India
Contact
Status	Withdrawn
Phase	N/A
Start date	February 1, 2020
Completion date	December 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05491135` - Hepatocyte Microbeads for Acute Liver Failure	Phase 1/Phase 2
Terminated	`NCT01937130` - Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF	Phase 2
Withdrawn	`NCT05940610` - The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure	Phase 1/Phase 2
Not yet recruiting	`NCT02833064` - Biomarkers in Liver Failure	N/A
Terminated	`NCT01875874` - Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)	Phase 2
Not yet recruiting	`NCT01435421` - Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery	N/A
Completed	`NCT00245310` - Indocyangreen Elimination in Cirrhosis and Acute Liver Failure	N/A
Withdrawn	`NCT03629015` - Safety Study of Stemchymal® in Acute Liver Failure	Phase 1
Recruiting	`NCT04621812` - Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
Not yet recruiting	`NCT06285253` - miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial	Phase 1
Recruiting	`NCT03882346` - Study to Evaluate Safety and Efficacy of LifeLiver in Acute or Acute-on-Chronic Liver Failure Patients	Phase 2
Recruiting	`NCT05689645` - F573 for Injection for the Treatment of Liver Injury/Failure	Phase 2
Not yet recruiting	`NCT05772585` - Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy
Completed	`NCT00655304` - The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure	N/A
Completed	`NCT00059267` - Prevention of Recurrent Hepatitis B After Liver Transplantation	N/A
Active, not recruiting	`NCT05413083` - Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis
Recruiting	`NCT05146336` - CytOSorb TreatMent Of Critically Ill PatientS Registry
Withdrawn	`NCT04089969` - Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct	N/A
Completed	`NCT02460510` - Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF	N/A
Completed	`NCT01872767` - Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver Failure	N/A